Search Within

Michael S Baum

Formats
  1. Journal Article (12)
  2. Meeting Abstract (7)
  3. Book Section (1)
Groups
  1. Cardiology (20)
  2. Department of Medicine (20)
  3. Division of Subspecialty Medicine (20)
  4. Solid Tumor Oncology Division (17)
  5. Genitourinary Oncology Service (12)
  6. Radiology, Department of (12)

More Groups

People
  1. Robert Motzer (12)
  2. Michelle Ginsberg (8)
  3. Darren Feldman (6)
  4. Patricia Fischer (5)
  5. Ellen Ronnen (4)
  6. Sujata Patil (4)

More People

Years
  1. 2016 (1)
  2. 2015 (1)
  3. 2014 (1)
  4. 2012 (2)
  5. 2011 (3)
  6. 2010 (2)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. American Journal of Hematology/Oncology (2)
  3. JNCI: Journal of the National Cancer Institute (2)
  4. American Journal of Clinical Oncology (1)
  5. Cancer (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. Haymarket Media Inc. (2)
  3. Oxford University Press (2)
  4. Springer (2)
  5. American Association for Cancer Research (1)
  6. Elsevier Inc. (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Fury, M. G.; Tuttle, R. M.; Ghossein, R.; Stambuk, H.; Baum, M.; Lisa, D.; Su, Y. B.; Shaha, A.; Pfister, D. G.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Feldman, D. R.; Baum, M. S.; Ginsberg, M. S.; Hassoun, H.; Flombaum, C. D.; Velasco, S.; Fischer, P.; Ronnen, E.; Ishill, N.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Feldman, D. R.; Ginsberg, M. S.; Baum, M.; Flombaum, C.; Hassoun, H.; Velasco, S.; Fischer, P.; Ishill, N. M.; Ronnen, E. A.; Motzer, R. J.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    Journal Article

    Klimek, V. M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas, K.; Wright, J. J.; Pandolfi, P. P.; Nimer, S. D.
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Capecitabine-induced coronary vasospasm
    Journal Article

    Goldsmith, Y. B.; Roistacher, N.; Baum, M. S.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Feldman, D. R.; Kondagunta, G. V.; Ronnen, E. A.; Fischer, P.; Chang, R.; Baum, M.; Ginsberg, M. S.; Ishill, N.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Superior efficacy of sunitinib compared with interferon as first-line therapy in patients with metastatic renal cell carcinoma
    Journal Article

    Patel, P. H.; Schwartz, L. H.; Baum, M. S.; Motzer, R. J.
    American Journal of Hematology/Oncology (2007)

    Fulltext@MSK | Save
  • Efficacy and safety of sunitinib as second-line therapy in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Feldman, D. R.; Baum, M. S.; Ginsberg, M.
    American Journal of Hematology/Oncology (2007)

    Fulltext@MSK | Save
  • A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Ronnen, E. A.; Kondagunta, G. V.; Lau, C.; Fischer, P.; Ginsberg, M. S.; Baum, M.; Kim, S. T.; Chen, I.; Baum, C. M.; Motzer, R. J.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Cardiac toxicity of 5FU: Does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience
    Meeting Abstract

    Pizzolato, J.; Baum, M. S.; Steingart, R. M.; Gonen, M.; Minsky, B. D.; Saltz, L. B.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save